9-Me-BC

β-Carbolines are pyridoindoles built from tryptophan. They are formed in the body and also arrive from outside it — in fried meat and fish, coffee, alcoholic drinks, fruit and, above all, tobacco smoke — and they have been measured in human plasma, cerebrospinal fluid and brain [4][5]. Daily dietary exposure to the common members norharman and harman has been estimated at a few micrograms per kilogram of body weight, with smoking the single largest contributor [5].

The family has a bad reputation, and it earned it. Several β-carbolines resemble MPTP, the compound that produces parkinsonism in humans, and their methylated cationic forms inhibit mitochondrial complex I and kill dopaminergic neurons; because they are found at higher concentrations in the brains of people with Parkinson's disease, they have been proposed as contributing causes of it [1]. One endogenous β-carboline ester is taken up specifically by neurons and triggers apoptosis through release of cytochrome c and apoptosis-inducing factor [6]. β-Carbolines also bind melanin with high affinity and are retained in pigmented tissue for up to 30 days after a single dose, which is one reason the neuromelanin-rich substantia nigra keeps coming up [7].

9-Me-BC is the exception that got a commentary in Journal of Neurochemistry titled "Good guys from a shady family" [8]. Methylation at the ring nitrogen N9 — rather than at N2, which produces the positively charged neurotoxic species — appears to flip the molecule from neuron-killing to neuron-stimulating. In primary mesencephalic culture it lowered lactate dehydrogenase release and propidium iodide staining, cut caspase-3 activity, raised ATP content, damped inflammation-related genes, and significantly increased the number of differentiated dopaminergic neurons while stimulating an entire panel of factors that specify them: Shh, Wnt1, Wnt5a, En1, En2, Nurr1, Pitx3, plus the markers Th, Dat and Aldh1a1 [1].

A follow-up called the profile a "tetrad": stimulation of tyrosine hydroxylase expression and neurite outgrowth, protection against acute toxins, regeneration of tyrosine-hydroxylase-positive neurons after chronic rotenone, and an anti-inflammatory shift with reduced microglial proliferation — together with a fall in α-synuclein protein [2]. The only in-vivo study delivered the compound into a rat's left cerebral ventricle for 14 days after 28 days of the neurotoxin MPP+. It reversed the striatal dopamine loss, restored substantia nigra cell counts to normal, raised complex I activity by roughly 80%, and induced BDNF, CDNF, cerebellin 1 precursor protein and CNTF [3].

The result that drew a nootropics audience is separate. Rats treated for ten days — but not five — learned the radial maze better, had higher dopamine in the hippocampal formation, and showed longer and more branched dendritic trees with more spines on dentate gyrus granule neurons [4]. That is a genuine cognitive result in healthy animals, which is rarer than it sounds. It is also a single study in one species, and nothing comparable has been done in a person.

The honest summary is that 9-Me-BC has an interesting and internally consistent preclinical file assembled over about fifteen years by a small circle of German laboratories, and a completely empty human one. The 2011 review from the same group asked whether it might be "a new anti-Parkinson drug" [9]; fifteen years later no trial has tested that question.

The mechanism is transcriptional, not receptor-driven. There is no evidence that 9-Me-BC binds a dopamine receptor or transporter with useful affinity. What it does instead is raise the expression of the machinery that makes and maintains dopaminergic neurons. In primary midbrain culture it increased tyrosine hydroxylase protein and transcript in neurons that already expressed dopa decarboxylase — that is, it switched on the rate-limiting enzyme in cells that were already partway to a dopaminergic phenotype rather than creating new cells — and it induced the transcription factors Gata2, Gata3, Creb1 and Crebbp alongside it [2]. The earlier culture study found the same pattern across a wider developmental panel including Nurr1 and Pitx3 [1]. Whether the extra dopaminergic neurons come from precursors, from previously tyrosine-hydroxylase-negative neurons, or from transdifferentiation was explicitly left open by the authors [1].

Astrocytes do part of the work. The 2020 study treated cortical and midbrain astrocyte cultures and found 9-Me-BC was anti-proliferative without being toxic: adenylate kinase release did not rise at any concentration from 10 to 150 µM, and viability actually increased by 12% at 90 µM and 20% at 150 µM [10]. Those astrocytes then raised their expression of factors that support dopaminergic neurons — artemin 3.2-fold, and TGF-β2, BDNF, Egln1 and Ncam1 more modestly [10]. Uptake into astrocytes appears to run through an organic cation transporter rather than the dopamine transporter, since the OCT blocker decynium-24 abolished the anti-proliferative effect concentration-dependently [10].

One pathway is required rather than merely associated. Adding the PI3K inhibitor LY294002 completely blocked the increase in tyrosine-hydroxylase-positive neurons [10]. PI3K/Akt is the common downstream node for neurotrophic factor signalling, so this is consistent with the effect running through growth-factor pathways rather than through a direct action on dopamine synthesis.

Enzyme inhibition is real but modest. 9-Me-BC inhibits human MAO-A with an IC50 of 1 µM and MAO-B with an IC50 of 15.5 µM [10]. MAO-A inhibition at low micromolar concentrations is a plausible contributor to the higher dopamine content measured in treated cultures and, possibly, to the higher hippocampal dopamine seen in rats [4][10]. It is also the one part of the mechanism with an obvious safety implication, because MAO-A inhibitors interact with tyramine and with serotonergic drugs — though no interaction study of any kind has been done with this molecule.

The energetic effect came with the in-vivo work. In rats given MPP+ and then 9-Me-BC, striatal mitochondrial complex I activity was about 80% higher than in MPP+ plus saline or in sham-operated animals, while two-dimensional gel electrophoresis and mass fingerprinting showed no change in the composition of the respiratory complexes themselves [3]. Since MPP+ poisons complex I, a drug that raises complex I activity while inducing neurotrophins is a sensible explanation for the restoration of dopamine and cell counts in that model.

The plasticity result is morphological. Ten days of treatment lengthened and branched the dendritic trees of dentate gyrus granule neurons and increased spine density, with higher dopamine in the hippocampal formation and better radial maze performance [4]. Five days did not do it. The delay fits a mechanism that works through gene expression and structural remodelling rather than acute neurotransmission, and it means any human equivalent — if one exists — would not be a same-day effect.

What the mechanism does not include is a demonstrated molecular sensor. Nobody has shown what 9-Me-BC binds first. Every step above is downstream of an unidentified initiating event.

There is no human safety data. Not a single published trial, case report or pharmacokinetic study has given 9-Me-BC to a person, so statements about its tolerability, dose ceiling, drug interactions or long-term effects would be invention.

What the preclinical record shows is reassuring as far as it goes. In astrocyte cultures, concentrations from 10 to 150 µM produced no rise in adenylate kinase release and no fall in viability [10]. In mesencephalic culture the compound reduced markers of cell injury and apoptosis rather than causing them [1]. The rat study reported restoration rather than damage [3]. None of that is a toxicology programme: there is no published repeat-dose toxicity study, no genotoxicity battery, no reproductive toxicity work and no LD50 in the references cited here.

Two class-level facts deserve to be stated rather than smoothed over. First, β-carbolines as a family include compounds that inhibit mitochondrial complex I and kill dopaminergic neurons, and the charged 2,9-dimethyl form is used as the toxin in the very experiments where 9-Me-BC is the protector [1][2]. The difference between the neuroprotective and the neurotoxic member of this family is a methyl group in a different place, which is a reason for care rather than confidence. Second, β-carbolines bind melanin with high affinity and are retained in pigmented tissue — including the neuromelanin-containing neurons most affected in Parkinson's disease — for up to 30 days after a single dose [7]. A compound with that disposition taken daily for months is not pharmacologically the same as one that clears.

9-Methyl-β-carbolines are also efficient photosensitisers. Under UVA excitation at physiological pH they generate oxidised purine residues, single-strand breaks, abasic sites and cyclobutane pyrimidine dimers in DNA [11]. That was a photochemistry study in a cuvette, not a measurement of risk in skin or eye, but it is a real and specific property of this exact substitution pattern.